证券代码：301267 证券简称：华厦眼科 公告编号：2025-022 华厦眼科医院集团股份有限公司 第三届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日上午以现场会议与通讯会议相结合的方式在公司会议室召开第三届董事会第 十次会议，会议通知于 2025 年 8 月 11 日以电子邮件和即时通讯的方式送达。 本次会议应出席董事 7 名，实际出席董事 7 名（其中：委托出席董事 1 名，董 事苏庆灿先生因个人原因无法亲自出席会议，委托董事陈凤国先生出席会议并 代为行使表决权）；公司监事和高管列席了本次会议。经全体参会董事一致推 举，本次会议由董事陈凤国先生主持，会议的召集、召开符合《中华人民共和 国公司法》《公司章程》等有关规定。 二、董事会会议审议情况 全体与会董事以投票表决方式审议通过以下议案： 表决结果：同意7票；反对0票；弃权0票。 该议案已经公司董事会审计委员会审议通过。 上述具体内容详见公司同日发布于巨潮资讯网（www. ...

华厦眼科8月24日披露半年报，公司上半年实现营业收入21.39亿元，同比增长4.31%；归属于上市公司 股东的净利润2.82亿元，同比增长6.20%；基本每股收益0.34元。 ...

华厦眼科医院集团股份有限公司 2025 年半年度报告全文 华厦眼科医院集团股份有限公司 2025 年半年度报告 2025 年 8 月 1 华厦眼科医院集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人苏庆灿、主管会计工作负责人陈凤国及会计机构负责人(会计 主管人员)陈鹭燕声明：保证本半年度报告中财务报告的真实、准确、完整。 除下列董事外，其他董事亲自出席了审议本次半年报的董事会会议： | 未亲自出席董事姓名 | 未亲自出席董事职务 | 未亲自出席会议原因 | 被委托人姓名 | | --- | --- | --- | --- | | 苏庆灿 | 董事长 | 因个人原因 | 陈凤国 | 本报告涉及未来发展规划和经营计划等前瞻性描述不构成公司对投资者的 实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理 解规划、计划、预测与承诺之间的差异。敬请投资者注意投资风险。 报告期内，公司主营业务、核心竞争力、主要财务指 ...

Company Overview - Huaxia Eye Hospital Group Co., Ltd. specializes in ophthalmology services, with key offerings including cataract projects, posterior segment projects, refractive projects, and comprehensive optometry projects [1] - As of the first quarter of 2025, the company reported revenue of 1.093 billion yuan, representing a year-on-year increase of 11.74%, while net profit was 150 million yuan, showing a year-on-year decrease of 4.00% [1] Financial Metrics - The company's closing stock price on August 15 was 20.67 yuan, with a PE ratio of 41.11 times and a total market capitalization of 17.363 billion yuan [1] - The average PE ratio for the healthcare services industry is 49.76 times, with a median of 64.18 times, placing Huaxia Eye Hospital at the 26th position within the industry [1][2] - The company has a sales gross margin of 44.97% as per the latest financial report [1] Institutional Holdings - As of the first quarter of 2025, five institutions hold shares in Huaxia Eye Hospital, all being funds, with a total holding of 3.5318 million shares valued at 6.8 million yuan [1]

Core Viewpoint - Huaxia Eye Hospital's stock closed at 20.53 yuan, up 3.01%, with a rolling PE ratio of 40.83, marking a new low in 80 days, and a total market value of 17.245 billion yuan [1] Group 1: Company Performance - For Q1 2025, the company reported revenue of 1.093 billion yuan, a year-on-year increase of 11.74%, and a net profit of 150 million yuan, reflecting a year-on-year decrease of 4.00% [1] - The company's gross profit margin stands at 44.97% [1] Group 2: Shareholder Information - As of March 31, 2025, the number of shareholders reached 20,981, an increase of 1,961 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 3: Industry Comparison - The average PE ratio for the medical services industry is 46.96, with a median of 54.55, placing Huaxia Eye Hospital at the 24th position within the industry [1] - The static PE ratio for Huaxia Eye Hospital is 40.23, and the price-to-book ratio is 2.92 [2]

Core Insights - The vision correction industry in China is experiencing rapid growth driven by policy support, market demand, and technological innovation [1][5][22] - The market size is projected to reach 215 billion yuan in 2024, with a year-on-year growth of 11.6% [1][14] - The industry has established a comprehensive treatment system combining surgical and optical correction methods [1][10] Policy Support - The Chinese government has implemented a series of policies to enhance eye health, including the "Comprehensive Prevention and Control of Myopia in Children and Adolescents Implementation Plan" [5][7] - Policies aim to create a management system covering prevention, treatment, and rehabilitation, promoting standardized and high-quality development in the industry [5][22] Market Demand - The number of myopic individuals in China has surpassed 600 million, with a significant increase in myopia rates across all age groups [8][12] - The myopia rate among high school students exceeds 80%, and projections suggest that the rate for the 16-24 age group may reach 94% [8][12] - This growing patient base provides a continuous driving force for the industry's development [1][8] Industry Structure - The vision correction industry has formed a complete industrial chain, with upstream focusing on optical materials and high-end equipment, while midstream includes the production of glasses and surgical devices [10][20] - The downstream market is served by medical institutions, optical centers, and e-commerce platforms, with private eye hospitals contributing over 60% of refractive surgeries [10][12] Competitive Landscape - The industry features a multi-layered competitive structure, with foreign brands dominating high-end markets while domestic brands accelerate their presence [20][21] - Key players include Aier Eye Hospital, Aibo Medical, and Opcon Vision, each with distinct market positions and strategies [21][20] Future Trends - The industry is expected to continue expanding due to policy-driven demand and technological advancements, with a focus on full-cycle management of eye health [22][24] - Innovations such as AI-assisted surgeries and domestic alternatives to imported products are reshaping the competitive landscape [24][25] - The trend towards service accessibility is being driven by private institutions expanding into lower-tier cities and the growth of online sales channels [25][22]

Market Overview - The Shanghai Composite Index closed at 3519.65 points, above the annual line, with a change of 0.27% [1] - The total trading volume of A-shares reached 14809.22 billion yuan [1] Stocks Breaking Annual Line - A total of 46 A-shares have surpassed the annual line today, with notable stocks including: - Siyuan Electric (002028) with a deviation rate of 7.62% - Huaming Equipment (002270) with a deviation rate of 2.75% - Tongyi Co., Ltd. (300538) with a deviation rate of 2.63% [1] Deviation Rate Rankings - The top stocks with the highest deviation rates from the annual line include: - Siyuan Electric: 10.00% increase, latest price 76.99 yuan, deviation rate 7.62% - Huaming Equipment: 3.25% increase, latest price 16.85 yuan, deviation rate 2.75% - Tongyi Co., Ltd.: 2.63% increase, latest price 16.02 yuan, deviation rate 2.63% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the annual line include: - Daqin Railway and *ST Haiyuan with minimal deviation rates [1]

证券代码：301267 证券简称：华厦眼科 公告编号：2025-021 华厦眼科医院集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指 引第 9 号——回购股份》等相关规定，华厦眼科医院集团股份有限公司（以下简 称"公司"或"本公司"）回购专用账户中的股份不参与本次权益分派。公司 2024 年年度权益分派以当前总股本 840,000,000 股剔除已回购股份 7,527,840 股 后的 832,472,160 股为基数，向全体股东每 10 股派发现金红利人民币 2.20 元（含 税），合计派发现金红利 183,143,875.20 元。 2、本次权益分派实施后计算除权除息价格时，以公司总股本（含回购股份， 即 840,000,000 股）折算后的每 10 股现金红利（含税）=现金分红总额/总股本（含 回购股份）*10=183,143,875.20 元/840,000,000 股*10=2.180284 元（保留六位小 数，最后一位直 ...

Core Viewpoint - Huaxia Eye Hospital Group, in collaboration with Shanghai University, Nova Coffee, and Shanghai Xin'ao Guangming Public Welfare Foundation, launched the "Eye Health Dry Eye Moisturizing Public Welfare Activity and Technology Innovation Platform Release Ceremony," introducing the first AI self-test tool for dry eye in China, named "Smart Eye Guardian" [1][2]. Group 1: AI Self-Test Tool - The "Smart Eye Guardian" mini-program is the first AI self-test tool for dry eye in China, allowing users to upload images and videos for quick, contactless preliminary diagnosis of dry eye symptoms [2][3]. - The program aims to address the increasing prevalence of dry eye, which affects approximately 360 million people in China, growing at a rate of 10% annually [3]. Group 2: Public Health Challenge - The World Health Organization reports that over 2 billion people globally spend more than 8 hours a day on screens, with about 35% experiencing dry eye symptoms [3]. - The rise of digital device usage has led to a significant increase in dry eye cases, highlighting the need for innovative solutions like the "Smart Eye Guardian" [3]. Group 3: Collaborative Initiatives - Huaxia Eye Hospital partnered with Nova Coffee to launch the "Good for Eyes" blueberry beverage, targeting the 20-45 age group, which faces higher risks of dry eye due to busy lifestyles and lack of awareness [4]. - The collaboration includes a public welfare project where 0.1 yuan from each "nourishing coffee" sold will be donated to a public welfare fund, promoting a "consumption equals public welfare" model [4]. Group 4: Community Engagement - Over 50 hospitals under Huaxia Eye Hospital will participate in eye health public welfare projects, conducting a series of dry eye care activities in the coming month [4]. - The initiative aims to fill the gap in dry eye health education and patient care, focusing on preventive measures and raising awareness among high screen-time populations [4]. Group 5: Professional Insights - Experts emphasized the importance of understanding the causes and development of dry eye, advocating for good lifestyle habits to prevent the condition [5]. - The misconception that dry eye is untreatable was addressed, with experts stating that all cases can be effectively treated once the underlying causes are identified [5].

Core Viewpoint - The collaboration between Huaxia Eye Hospital Group, Shanghai University, Nova Coffee, and Shanghai Xin'ao Guangming Public Welfare Foundation aims to redefine the boundaries of ophthalmic healthcare through innovation and integration of industry, academia, and research [1][3]. Group 1: Industry Collaboration - The establishment of the "Ophthalmic Technology Joint Transformation Center" signifies a commitment to the transformation and application of ophthalmic technologies, leveraging Shanghai University's research strengths and Huaxia Eye Hospital's clinical experience [3]. - The center aims to promote deep integration of industry, academia, and research, aligning with China's health strategy to enhance technological innovation and industrial upgrading [3]. Group 2: AI and Healthcare Innovation - The launch of the "Smart Eye Guardian" AI self-test tool marks a significant advancement in dry eye screening, filling a gap in domestic intelligent screening and extending traditional hospital screening to end-users [5]. - With over 2 billion people globally using screens for more than 8 hours daily, and 35% experiencing dry eye symptoms, the tool addresses a pressing healthcare need [5]. Group 3: Public Welfare Initiatives - Huaxia Eye Hospital has initiated a public welfare project by donating 10,000 dry eye experience services to Shanghai University students and alumni, integrating professional medical services with high eye-use consumer scenarios [7]. - The collaboration with Nova Coffee aims to make public welfare services more accessible and participatory, blending corporate activities with social responsibility [7][8]. - The initiative reflects a forward-looking approach to the "big health" ecosystem, exploring innovative models that combine healthcare and consumer engagement [8].